

# Retinopathy of prematurity screening at $\geq 30$ weeks: urinary NTpro-BNP performance

Ewer, Andrew

DOI:

[10.1111/apa.14354](https://doi.org/10.1111/apa.14354)

License:

None: All rights reserved

Document Version

Peer reviewed version

Citation for published version (Harvard):

Ewer, A 2018, 'Retinopathy of prematurity screening at  $\geq 30$  weeks: urinary NTpro-BNP performance', *Acta Paediatrica*. <https://doi.org/10.1111/apa.14354>

[Link to publication on Research at Birmingham portal](#)

## Publisher Rights Statement:

This is the peer reviewed version of the following article:

Berrington, J. E., Clarke, P., Embleton, N. D., Ewer, A. K., Geethanath, R., Gupta, S., Lal, M., Oddie, S., Shafiq, A., Vasudevan, C. and Bührer, C. (2018), Retinopathy of prematurity screening at  $\geq 30$  weeks: urinary NTpro-BNP performance. *Acta Paediatr.* which has been published in final form at doi:10.1111/apa.14354.

This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving

## General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

## Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

## **Retinopathy of prematurity screening at $\geq 30$ weeks: urinary NTpro-BNP performance**

Berrington JE,<sup>1,2</sup> Clarke P<sup>3</sup>, Embleton ND,<sup>1,4</sup> Ewer AK<sup>5</sup>, Geethanath R<sup>6</sup>, Gupta S<sup>7</sup>, Lal M<sup>8</sup>, Oddie S<sup>9</sup>, Shafiq A<sup>10</sup>, Vasudevan C<sup>9</sup> and Bühner C<sup>11</sup>

<sup>1</sup>Newcastle Neonatal Service, Newcastle upon Tyne Hospitals NHS Foundation Trust,

<sup>2</sup>Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK, <sup>3</sup>Norfolk and

Norwich University Hospitals NHS Foundation Trust, UK, <sup>4</sup>Institute of Health and Society,

Newcastle University, Newcastle upon Tyne, UK, <sup>5</sup>Birmingham Womens Hospital,

Birmingham, UK, <sup>6</sup>City Hospitals, Sunderland, UK, <sup>7</sup>University Hospital of North Tees,

Stockton, UK, <sup>8</sup>South Tees NHS Foundation Trust, UK, <sup>9</sup>Bradford teaching Hospitals NHS

Foundation Trust, UK, <sup>10</sup>Department of ophthalmology, Newcastle Upon Tyne Hospitals NHS

Foundation Trust, Newcastle upon Tyne, UK, <sup>11</sup>Charité Universitätsmedizin, Berlin, Germany

**Correspondence** – Janet Berrington, Consultant Neonatal Paediatrician, Newcastle Neonatal

Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Queen Victoria Road,

Newcastle Upon Tyne, NE 1 4LP, UK. E-mail: janet.berrington@nuth.nhs.uk Phone 0191

2825197 Fax 0191 2825038

### **Running Title**

Urinary NTproBNP ROP & infants  $>30$  weeks

## **Abstract**

### **Aim**

Urinary N-terminal B-type natriuretic peptide NTproBNP levels are associated with the development of retinopathy of prematurity (ROP) in infants <30 weeks gestation. The incidence of ROP in more mature infants who meet other ROP screening criteria is very low. We therefore aimed to test whether urinary NTproBNP predicted ROP development in these infants.

### **Methods**

Prospective observational study in 151 UK infants  $\geq 30+0$  weeks gestation but also <32 weeks gestation and/or <1501g, to test the hypothesis that urinary NTproBNP levels on day of life (DOL) 14 and 28 were able to predict ROP development.

### **Results**

Urinary NTproBNP concentrations on day 14 and day 28 of life did not differ between infants with and without ROP (medians 144mcg/ml vs 128mcg/ml respectively,  $p=0.86$  on DOL 14 and medians 117mcg/ml vs 94mcg/ml respectively,  $p=0.64$  on DOL28).

### **Conclusion**

The association previously shown for infants <30 completed weeks between urinary NTproBNP and development of ROP was not seen in more mature infants. Urinary NTproBNP does not appear helpful in rationalizing direct ophthalmoscopic screening for ROP in more mature infants, and may suggest a difference in pathophysiology of ROP in this population.

## Key Notes

- 1) Published data for infants <30 completed weeks gestation suggests that urinary NTproBNP levels might contribute to identifying infants at risk from [retinopathy of prematurity \(ROP\)](#)
- 2) We showed that this is not true for more mature infants who still fulfil UK screening criteria
- 3) This difference may imply different pathophysiology of ROP development in more mature infants

## Abbreviations

NTproBNP: Urinary N-terminal B-type natriuretic peptide

REDEXAM: REDucing Eye EXAMinations in preterm infants

ROP: retinopathy of prematurity

UK: United Kingdom

## Introduction

Visual impairment as a result of retinopathy of prematurity (ROP) is potentially preventable by screening (1), but at present screening is largely dependent on direct ophthalmoscopy, which requires the availability of ophthalmologists willing and able to perform this.

Although telemedicine and digital photography have improved access in some areas, costs, training expertise and other practicalities restrict universal screening (2-4). This and the physical discomfort and instability caused to the infant (5), and distressing nature of the examination to the family, mean that non-invasive markers of ROP development have been sought, and algorithms generated to attempt to maximize the performance of features associated with ROP development to accurately predict this (6,7). To date, no 'ideal' biomarkers of ROP have been identified and sufficiently tested, but urinary B-type natriuretic peptide (BNP) shows promise (8). Proteolytic cleavage of a precursor protein yields biologically active BNP and an inert N-terminal fragment, NTproBNP (amino acids 1-76). Measuring NTproBNP concentrations is routine in cardiac failure in children and neonates (9,10) and often available in routine health provision laboratories relatively cheaply. Concentrations of NTproBNP in blood parallel those in the urine, making non-invasive measurement possible (11). In a single-center pilot study, we showed that urinary NTproBNP/creatinine ratios (UNBCR) in the first month were significantly elevated in preterm infants who developed severe ROP, compared to controls (8). To further assess the predictive power of urinary NTproBNP concentrations and UNBCR during the first month of life to allow early identification of infants at high or low risk of severe ROP, we conducted a prospective observational study (REDEXAM, REDucing Eye EXAMinations in preterm infants) in neonatal intensive units in 8 European and Middle East countries (12).

This second study showed a strong association between urinary NTproBNP measurements on day 14 and 28 of life and subsequent ROP development, in a cohort of 967 infants of  $\leq 29+6$  weeks gestation (12). This is potentially important as this cheap, readily available test could help reduce or target direct ophthalmoscopy reducing either the number of individuals ever needing to be screened, or the number of screens undertaken in an individual, or both.

Gerull *et al* (13) recently confirmed the low incidence of retinopathy of prematurity( ROP) in Switzerland in more mature infants than those included in our second study - those between 30+0 and 31+6 weeks gestation. There was a very low incidence of any ROP (1.7% (56/3222)) and severe or treated ROP (0.16% (5/3222)) and these authors called for a review of screening criteria. Given the relatively large numbers of more mature infants compared to very immature infants, and the low rate of ROP in these more mature infants, the utility of urinary NTproBNP to predict ROP development in more mature infants who still fulfil screening criteria, is important. We therefore tested the hypothesis that urinary NTproBNP in the first month of life, in infants  $\geq 30+0$  weeks fulfilling UK ROP screening criteria by virtue of gestation ( $< 32$  completed weeks) birth weight ( $< 1501$ g) or both, would predict ROP development. To do this we applied the methodology of our previous study (14) to infants with gestations  $\geq 30+0$  weeks, born only in the UK.

## **Methods**

### **Study setting**

7 neonatal intensive care units in the United Kingdom participated between November 2013 and May 2015. Ethical approval was obtained from Newcastle and North Tyneside 2 ethics committee.

### **Patients and measurements**

Infants with a gestational age  $\geq 30+0$  completed weeks gestation and/or  $< 32+0$  or  $< 1501$ g, alive at 10 days were eligible. Written informed parental consent was obtained. Urine was collected on DOL (day of life)14 and DOL28 (or as close as possible) by each center by their usual method (cotton wool balls or pads in the nappy, bags or clean catches by staff or parents at routine nappy changes) and stored at  $-80^{\circ}\text{C}$  until analysis. Urinary NTproBNP concentrations were determined at one laboratory on one site (Newcastle Upon Tyne, UK) in batches by standard hospital laboratory automated commercial chemiluminescent sandwich immunoassays (Roche Modula P E170 run on a cobas e 411 analyser) as described previously (8,15). Urines with a level lower than the limits of detection of the assay were attributed the lower level (50 mcg/l). We also recorded infant weight on DOL14 and DOL28. Proportional weight gain was calculated by dividing the gain of the infant's weight since birth on DOL14 or DOL28, respectively, by birth weight.

### **ROP outcomes**

ROP screening examinations were unaffected by study participation, undertaken by serial binocular indirect ophthalmoscopy and carried out by experienced local ophthalmologists according to local and national guidelines unaware of urinary NTproBNP concentrations

(14). ROP was staged according to the International Classification of Retinopathy of Prematurity (16) and allocated treatment according to the Early Treatment for Retinopathy of Prematurity criteria (17).

### **Statistical analysis**

NTproBNP results for infants with known ROP outcome and at least one urinary NTproBNP concentration measured were analysed using SPSS 23.0 (SPSS Inc, Chicago, IL). As NTproBNP results and other variables lacked a normal distribution, data are presented as median and range. We assessed the strength of association between continuous variables by Spearman rank order coefficients. Differences in the distribution of continuous variables were assessed by the Mann-Whitney U test.

### **Results**

A total of 151 infants, 77 (51%) male, of median gestation 31.0 (range 30.0 – 37.0) weeks and median birth weight 1420g (range 640-2430g) participated, including 105 singletons, 39 twins (some of whom had non-surviving siblings), one triplet set and one quad set.

Five infants died before ROP screening was complete. Of surviving infants, 11 (7.5%) had any ROP: two (1.4%) stage 1, eight (5.5%) stage 2 and one (0.7%) stage 3 (zone 3 only). No infant was ever treated for ROP, and all ROP resolved.

We found that ROP of any grade was restricted to infants  $\leq 32+0$  weeks gestational age (n=123). None of the more mature infants who entered the study had any signs of ROP. In contrast to the cohort  $<30+0$  weeks, there were no significant differences between infants with ROP, as opposed to infants without ROP for proportional weight gain or urinary



NTproBNP concentrations on day 14 and day 28 of life (Table 1) . Urinary NTproBNP concentrations were poorly associated with birthweight for this cohort (figure 1).

## **Discussion**

Successfully identifying a non-invasive biomarker for development of ROP would have significant financial, family and infant benefits. Urinary NTproBNP appeared promising in pilot work (8), and in a larger population of relatively immature infants (<30+0 weeks gestation (12). However in the present study done in more mature infants who are still judged at risk of ROP by current screening criteria, a relationship between urinary NTproBNP and the development of ROP has not been demonstrated.

Although this was a relatively small study of 151 infants, this cohort is larger than that in the original pilot study (n=136) where a correlation was seen between ROP development and urinary NTproBNP, and a correlation was previously seen in the less mature UK infants (12). It is still possible that a larger study would show a relationship, but any study will suffer from the impact of assessing any test for ROP in a very low incidence population.

Little is known about the role of BNP in development of ROP. The lack of correlation between urinary NTproBNP levels and ROP in more mature infants could indicate different pathophysiology of either ROP development or BNP release in comparison to less mature infants. Equally, in the more immature population urinary NTproBNP may simply act as a proxy measure of 'sickness' related to immaturity which subsequently relates to risk of ROP development. In the more mature population, where ROP development is rare, 'sickness' may then influence BNP levels but not ROP development, causing the relationship to be lost.

We did not collect more extensive clinical data to allow this hypothesis to be tested further in this study, but future studies could explore this possibility, as well as being larger.

We conclude that in this UK cohort urinary NTproBNP based levels for risk factors for ROP established for more immature infants fail to identify infants of 30+0 weeks or more who might benefit from, or not require, screening ophthalmoscopy. Differences in other morbidities or potentially different pathophysiology of ROP development in more mature infants may explain this loss of correlation.

### **Acknowledgements**

We gratefully acknowledge all parents and infants who participated, Susan McLellen (biochemist, Royal Victoria Infirmary, Newcastle), research teams and nurses especially Suzanne Bell, Karen Few, Wendy Cheadle, Rachel Jackson, Eileen Walton, Rachel Wane, Linda Shah and Thomas Skeath and Stefan Zalewski (research fellows, Newcastle neonatal service) for their help in keeping the study running smoothly.

### **Statement of financial support**

The study has received financial support from the BLISS innovation grant (London, UK)

### **Disclosure statement**

There are no conflicts of interests to be disclose

## References

1. Jefferies AL and Canadian Paediatric Society, Fetus and Newborn Committee 2016 Retinopathy of prematurity: An update on screening and management. *Paediatr Child Health* 21:101-108.
2. Fierson WM and Capone A, Jr., American Academy of Pediatrics Section on O, American Academy of Ophthalmology AAOCO 2015 Telemedicine for evaluation of retinopathy of prematurity. *Pediatrics* 135:e238-254.
3. Zepeda-Romero LC, Gilbert C 2015 Limitations in ROP programs in 32 neonatal intensive care units in five states in Mexico. 2015 *Biomed Res Int*:712624.
4. Vinekar A, Jayadev C, Kumar S, Mangalesh S, Dogra MR, Bauer NJ *et al* 2016 Impact of improved neonatal care on the profile of retinopathy of prematurity in rural neonatal centers in India over a 4-year period. *Eye Brain* 8:45-53.
5. Dhaliwal CA, Wright E, McIntosh N, Dhaliwal K and Fleck BW 2010 Pain in neonates during screening for retinopathy of prematurity using binocular indirect ophthalmoscopy and wide-field digital retinal imaging: a randomised comparison. *Arch Dis Child Fetal Neonatal Ed* 95:F146-148.
6. Jung JL, Wagner BD, McCourt EA, Palestine AG, Cerda A, Cao JH, *et al* 2017 Validation of WINROP for detecting retinopathy of prematurity in a North American cohort of preterm infants. *J AAPOS*.
7. Gurwin J, Tomlinson LA, Quinn GE, Ying GS, Baumritter A and Binenbaum G, Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study Group and the Telemedicine Approaches to Evaluating Acute-Phase Retinopathy of Prematurity Cooperative Group 2017 A tiered approach to retinopathy of prematurity screening (TARP) using a weight gain predictive model and a telemedicine system. *JAMA Ophthalmol*. doi: 10.1001/jamaophthalmol.2016.5203. [Epub ahead of print]

8. Czernik C, Metze B, Müller C, Müller B, and Bühner C 2011 Urinary N-terminal B-type natriuretic peptide predicts severe retinopathy of prematurity. *Pediatrics* 128:e545-549.
9. Nir A and Nasser N 2005 Clinical value of NT-ProBNP and BNP in pediatric cardiology. *J Card Fail* 11:S76-80.
10. Sugimoto M, Manabe H, Nakau K, Furuya A, Okushima K, Fujiyasu H, *et al* 2010 The role of N-terminal pro-B-type natriuretic peptide in the diagnosis of congestive heart failure in children. - Correlation with the heart failure score and comparison with B-type natriuretic peptide. *Circ J* 74:998-1005.
11. Kurihara N, Miwa M, Matsuzaki Y, Hokuto I, Kikuchi H, Katano S *et al* 2011 Usefulness of measurement of urinary N-terminal pro-brain natriuretic peptide in neonatal period. *Pediatr Int* 53:608.
12. Bühner C, Erdeve Ö, van Kaam A, Berger A, Lechner E, Bar-Oz B *et al* N-terminal B-type natriuretic peptide urinary concentrations and retinopathy of prematurity. *Pediatr Res* 2017 Jul 24. doi: 10.1038/pr.2017.179. [Epub ahead of print] PubMed PMID: 28738027.
13. Gerull R, Brauer V, Bassler D, Laubscher B, Pfister R, Nelle M *et al* Swiss Neonatal Network & Follow-up Group. Incidence of retinopathy of prematurity (ROP) and ROP treatment in Switzerland 2006-2015: a population-based analysis. *Arch Dis Child Fetal Neonatal Ed* 2017 Sep 15. pii: fetalneonatal-2017-313574. doi: 10.1136/archdischild-2017-313574. [Epub ahead of print] PubMed PMID: 28916563.
14. UK Retinopathy of prematurity guideline, 2008. Royal College of Ophthalmologists & Royal College of Paediatrics and Child Health.

15. Joseph L, Nir A, Hammerman C, Goldberg S, Ben Shalom E and Picard E 2010 N-terminal pro-B-type natriuretic peptide as a marker of bronchopulmonary dysplasia in premature infants. *Am J Perinatol* 27:381-386.
16. International Committee for the Classification of Retinopathy of Prematurity 2005 The International Classification of Retinopathy of Prematurity revisited. *Arch Ophthalmol* 123:991-999.
17. Early Treatment For Retinopathy Of Prematurity Cooperative Group 2003 Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. *Arch Ophthalmol* 121:1684-1694.

Figure 1

Relationship between NTproBNP and birth weight